EU application for nimotuzumab for pediatric glioma withdrawn
This article was originally published in Scrip
Executive Summary
Oncoscience AG has withdrawn its application to the EMEAfor marketing authorisation of the EGFR-targeted drug nimotuzumab for the treatment of paediatric glioma (brain cancer), saying that it was not able to adequately address the concerns of the CHMP regarding the quality and efficacy of the medicine within the required time schedule.